Yupelri

Chemical Namerevefenacin
Dosage FormNebulizer (oral inhalation; 175 mcg)
Drug ClassAnticholinergics
SystemRespiratory
CompanyMylan Ireland Ltd
Approval Year2018

Indication

  • To maintain treatment of chronic obstructive pulmonary disease
Last updated on 11/4/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Yupelri (Revefenacin) Prescribing Information 2019Mylan Specialty L.P., Morgantown, WV